Mark Wildgust, Vice President, Global Medical Affairs, Oncology at The Janssen Pharmaceutical Companies of Johnson and Johnson, shared a post on X:
“Excited to see the Monumental3 data being presented here EHA meeting and now published in the NEJM. Congratulations Peter Voorhees.”
Title: Talquetamab–Daratumumab in Relapsed or Refractory Myeloma
Authors: Roberto Mina, Meral Beksac, Paula Rodríguez-Otero, Wenming Chen, María-Victoria Mateos, Jian Li, Philippe Moreau, Yael Cohen, Chang-Ki Min, Tomas Jelinek, Jing Christine Ye, Hila Magen, Samuel Rubinstein, Weijun Fu, Vania Hungria, Guldane Cengiz Seval, Joao Samuel Farias, Jakub Radocha, Senem Maral, Mehmet Turgut, Youngil Koh, Daniel O’Leary, Jayr Schmidt Filho, Raymond Thertulien, Gang An, Shang-Yi Huang, Sebastian Grosicki, Agata Tyczyńska, Rahul Banerjee, Matthew Pianko, Joaquín Martínez-López, Pawel Steckiewicz, Dai Maruyama, Kentaro Fukushima, Albert Oriol, Jordi Lopez Pardo, Hartmut Goldschmidt, Charlotte Pawlyn, Aurore Perrot, Elena Zamagni, Meletios Dimopoulos, Leo Rasche, Jaszianne Tolbert, William Terry, Christelle Courtoux, Xiao Liu, Sandra Vasey, Kaitlyn Connors, Mariacristina Festa, Christoph Heuck, Angélique Langlois, Lisa O’Rourke, Jiangxiu Zhou, Xiang Qin, Jiashen Lu, Joy Gong, Diego Vieyra, Peter Voorhees
Read the Full Article.

Other articles featuring Mark Wildgust on OncoDaily.